Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
Pamela C Proud, Daphne Tsitoura, Robert J Watson, Brendon Y Chua, Marilyn J Aram, Kevin R Bewley, Breeze E Cavell, Rebecca Cobb, Stuart Dowall, Susan A Fotheringham, Catherine MK Ho, Vanessa Lucas, Didier Ngabo, Emma Rayner, Kathryn A Ryan, Gillian S Slack, Stephen Thomas, Nadina I Wand, Paul Yeates, Christophe Demaison Show all
EBioMedicine | Elsevier BV | Published : 2021
BACKGROUND: The novel human coronavirus SARS-CoV-2 is a major ongoing global threat with huge economic burden. Like all respiratory viruses, SARS-CoV-2 initiates infection in the upper respiratory tract (URT). Infected individuals are often asymptomatic, yet highly infectious and readily transmit virus. A therapy that restricts initial replication in the URT has the potential to prevent progression of severe lower respiratory tract disease as well as limiting person-to-person transmission. METHODS: SARS-CoV-2 Victoria/01/2020 was passaged in Vero/hSLAM cells and virus titre determined by plaque assay. Challenge virus was delivered by intranasal instillation to female ferrets at 5.0 × 106 pfu..View full abstract